论文部分内容阅读
Background:Cirrhosis is a common complication of chronic hepatitis B.It remains unclear if viral and biochemical parameters at baseline affect virological response to entecavir and therefore warrant investigation.In the present study,we aimed to evaluate the efficacy of entecavir therapy by monitoring virological response at the end of the 3rd month of treatment and try to figure out whether baseline factors could help predict it in a cohort of hepatitis B virus (HBV) compensated cirrhosis patients and to determine the cut-off value of a predicting parameter.Methods:A total of 91 nucleos(t)ide-na(i)ve patients with HBV induced cirrhosis (compensatory stage) were enrolled in a prospective cohort.HBV DNA and alanine aminotransferase (ALT) were tested at baseline and monitored every 3-6 months after starting therapy.Results:Of all 91 patients,the median follow-up time was 12 (9-24) months.Overall,64 patients (70.3％) achieved virological response in the 3rd month.Univariate analysis showed that the 3rd month virological response can be predicted by baseline HBV DNA levels (P ＜ 0.001,odds ratio [OR]:2.13,95％ confidence interval [CI]:1.44-3.15),ALT value (P =0.023,OR:1.0 1,95％ CI:1.00-1.01) and hepatitis B e antigen (HBeAg) negativity (P=0.016,OR:0.30,95％ CI:0.11-0.80).Multiple regression analysis showed baseline HBV DNA level was the only parameter related to full virological response.Higher baseline HBV DNA strata indicated a higher probability that HBV DNA remains detectable at the 3rd month (P =0.001).Area under receiver operating characteristic curve for determining the 3rd month virological response by baseline HBV DNA was 77.6％ (95％ CI:66.7-85.2％),with a best cut-off value of 5.8 log10.Conclusions:Baseline HBV DNA,HBeAg negativity,and ALT were independent factors contributing to virological response at the 3rd month.Further,multiple regression showed that HBV DNA level was the only parameter predicting full virological response as early as the 3rd month,in this cirrhosis cohort.